[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma]

Marie-Sophie Minot-This; Julien Edeline

doi:10.1016/j.bulcan.2020.11.011

[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma]

Bull Cancer. 2021 Feb;108(2):139-140. doi: 10.1016/j.bulcan.2020.11.011. Epub 2021 Feb 2.

[Article in French]

Authors

Marie-Sophie Minot-This¹, Julien Edeline²

Affiliations

¹ Institut Gustave-Roussy, Sorbonne Université, service d'oncologie digestive, 94800 Villejuif, France. Electronic address: ms.minot@gmail.com.
² Centre hospitalier universitaire de Rennes, centre Eugène-Marquis, service d'oncologie digestive, 35000 Rennes, France.

PMID: 33546873
DOI: 10.1016/j.bulcan.2020.11.011

No abstract available

Keywords: Anti-PD-L1; Anti-VEGF; Anti-angiogènes; Antiangiogenics; Carcinome hépato-cellulaire; Hepatocellular carcinoma; Immune checkpoint inhibitors; Inhibiteurs des points de contrôle immuns; Programmed death-ligand 1; Vascular Endothelial Growth Factor.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
Bevacizumab / adverse effects
Bevacizumab / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / mortality
Confidence Intervals
Humans
Immunotherapy / methods
Liver Neoplasms / drug therapy*
Liver Neoplasms / mortality
Proportional Hazards Models
Sorafenib / adverse effects
Sorafenib / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
B7-H1 Antigen
Bevacizumab
atezolizumab
Sorafenib